Diabetes Care:青少年T2DM患者高血压和肾病患病率急剧上升

2013-06-16 Diabetes Care dxy

在青少年2型糖尿病患者中,关于高血压和微量白蛋白尿的发生和进展的研究资料十分有限。针对这种情况,来自美国华盛顿大学的Laura Pyle博士等人进行了一项研究,即TODAY临床研究。研究小组人员对TODAY临床试验的患者的高血压和微量白蛋白尿进行评估,并分析治疗方式、血糖控制、性别和民族/种族对二者的影响。研究发现,青少年2型糖尿病患者高血压和微量白蛋白尿患病率随时间推移逐渐增高。性别、高BMI和

在青少年2型糖尿病患者中,关于高血压和微量白蛋白尿的发生和进展的研究资料十分有限。针对这种情况,来自美国华盛顿大学的Laura Pyle博士等人进行了一项研究,即TODAY临床研究。研究小组人员对TODAY临床试验的患者的高血压和微量白蛋白尿进行评估,并分析治疗方式、血糖控制、性别和民族/种族对二者的影响。研究发现,青少年2型糖尿病患者高血压和微量白蛋白尿患病率随时间推移逐渐增高。性别、高BMI和血糖控制是高血压和微量白蛋白尿发生的危险因素。研究结果在线发表于2013年6月的美国《糖尿病治疗》(Diabetes Care)杂志上。

这是一项队列研究,研究对象为699名青少年,年龄10-17岁,2型糖尿病病程<2年、BMI≥85%、二甲双胍治疗后HbA1c≤8%、血压(BP)可控、计算的肌酐清除率>70 mL/min。患者随机分配接受二甲双胍,二甲双胍联合罗格列酮或二甲双胍联合强化生活方式干预治疗。主要研究结果为6个月后血糖控制失败或代谢失调,需要注射胰岛素。采用标准疗法积极治疗高血压和微量白蛋白尿,以维持BP<130/80 或年龄、性别和高度小于第95百分位,以及微量白蛋白尿<30mg/mg。

结果显示,319名患者(45.6%)达到主要研究结果,基线高血压患病率为11.6%,研究结束时为33.8%(平均随访时间3.9年)。男性和高BMI显著增加高血压风险。基线微量白蛋白尿患病率为6.3%,研究结束时升高到16.6%。不同组别、性别和民族/种族间,诊断的微量白蛋白尿没有显著区别,但是高水平HbA1c与发生微量白蛋白尿的风险显著相关。

研究表明,尽管对糖尿病采取了治疗,但是随着时间推移,青少年2型糖尿病患者高血压和微量白蛋白尿患病率仍增高。高血压的最大危险因素是性别(男性发病率高)和高BMI。微量白蛋白尿的危险因素则与血糖控制更为密切相关。

Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes: The TODAY clinical trial.
OBJECTIVE
Among adolescents with type 2 diabetes, there is limited information regarding incidence and progression of hypertension and microalbuminuria. Hypertension and microalbuminuria assessments made during the TODAY clinical trial were analyzed for effect of treatment, glycemic control, sex, and race/ethnicity.
RESEARCH DESIGN AND METHODS
A cohort of 699 adolescents, 10-17 years of age, <2 years duration of type 2 diabetes, BMI ≥85%, HbA1c ≤8% on metformin therapy, controlled blood pressure (BP), and calculated creatinine clearance >70 mL/min, were randomized to metformin, metformin plus rosiglitazone, or metformin plus intensive lifestyle intervention. Primary study outcome was loss of glycemic control for 6 months or sustained metabolic decompensation requiring insulin. Hypertension and microalbuminuria were managed aggressively with standardized therapy to maintain BP <130/80 or <95th percentile for age, sex, and height and microalbuminuria <30 μg/mg.
RESULTS
In this cohort, 319 (45.6%) reached primary study outcome, and 11.6% were hypertensive at baseline and 33.8% by end of study (average follow-up 3.9 years). Male sex and higher BMI significantly increased the risk for hypertension. Microalbuminuria was found in 6.3% at baseline and rose to 16.6% by end of study. Diagnosis of microalbuminuria was not significantly different between treatment arms, sex, or race/ethnicity, but higher levels of HbA1c were significantly related to risk of developing microalbuminuria.
CONCLUSIONS
Prevalence of hypertension and microalbuminuria increased over time among adolescents with type 2 diabetes regardless of diabetes treatment. The greatest risk for hypertension was male sex and higher BMI. The risk for microalbuminuria was more closely related to glycemic control.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759308, encodeId=363c1e59308f5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu May 22 14:35:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717711, encodeId=11a11e17711f5, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Jul 24 12:35:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636698, encodeId=0de916366989a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 28 21:35:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901111, encodeId=cdd5190111159, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 02 01:35:00 CST 2014, time=2014-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250389, encodeId=0b0d125038945, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Jun 18 08:35:00 CST 2013, time=2013-06-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759308, encodeId=363c1e59308f5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu May 22 14:35:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717711, encodeId=11a11e17711f5, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Jul 24 12:35:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636698, encodeId=0de916366989a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 28 21:35:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901111, encodeId=cdd5190111159, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 02 01:35:00 CST 2014, time=2014-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250389, encodeId=0b0d125038945, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Jun 18 08:35:00 CST 2013, time=2013-06-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759308, encodeId=363c1e59308f5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu May 22 14:35:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717711, encodeId=11a11e17711f5, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Jul 24 12:35:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636698, encodeId=0de916366989a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 28 21:35:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901111, encodeId=cdd5190111159, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 02 01:35:00 CST 2014, time=2014-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250389, encodeId=0b0d125038945, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Jun 18 08:35:00 CST 2013, time=2013-06-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1759308, encodeId=363c1e59308f5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu May 22 14:35:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717711, encodeId=11a11e17711f5, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Jul 24 12:35:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636698, encodeId=0de916366989a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 28 21:35:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901111, encodeId=cdd5190111159, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 02 01:35:00 CST 2014, time=2014-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250389, encodeId=0b0d125038945, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Jun 18 08:35:00 CST 2013, time=2013-06-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1759308, encodeId=363c1e59308f5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu May 22 14:35:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717711, encodeId=11a11e17711f5, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Jul 24 12:35:00 CST 2013, time=2013-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636698, encodeId=0de916366989a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 28 21:35:00 CST 2014, time=2014-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901111, encodeId=cdd5190111159, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 02 01:35:00 CST 2014, time=2014-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250389, encodeId=0b0d125038945, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Jun 18 08:35:00 CST 2013, time=2013-06-18, status=1, ipAttribution=)]

相关资讯

Nat. Rev. Endocrinol:寻找更佳T2DM治疗方法之路漫漫修远兮

重要研究进展: 胰岛素治疗不会增加新诊断T2DM患者的心血管疾病或癌症风险; 对新诊断T2DM患者而言,积极主动维持血糖控制的方法(提前采用添加疗法而不是等到血糖治疗目标被突破后才开始)能 够保持6年内血糖水平接近正常; 加强T2DM患者血糖治疗有助于保持残留的β细胞功能,并维持3年以上; 二甲双胍仍然是治疗T2DM的基石,甚至是那些肾损伤的患者(估算肾小球滤过率≥30ml/mi

JCEM:T2DM胰岛素治疗增加糖尿病相关并发症

胰岛素在2型糖尿病(T2DM)治疗中的安全性最近遭受质疑。为了描述2型糖尿病患者降血糖治疗相关不良事件的风险。来自英国加的夫药物研究中心Craig J Currie教授及其团队进行了一项研究,该研究发现,在2型糖尿病患者,外源性胰岛素治疗与糖尿病相关并发症、癌症和全因死亡率风险增加有关。该研究结果在线发表在2013年2月的《临床内分泌代谢杂志》(The journal of clinical en

JCEM:湘雅医院刘昭前发现Ser165Pro和Ser257Pro多态性与T2DM相关

为了探讨在中国人群,两种新型β3–肾上腺素能受体(ADRB3)基因多态性(Ser165Pro和Ser257Pro)与2型糖尿病(T2DM)的关系,来自中 南大学湘雅医学院的刘昭前教授及其团队进行了一项研究(Two Novel Functional Single Nucleotide Polymorphisms of ADRB3Are Associated With Type 2 Diabetes

Diabetes Care:临床和亚临床大血管疾病标志物可预测老年T2DM患者认知减退

大血管疾病促使2型糖尿病患者认知加速减退的风险增加。为了确定在认知健康的老年2型糖尿病患者中大血管疾病指标与认知改变的相关性,来自英国苏格兰爱丁堡大学人口健康科学中心的Price博士等人进行了一项研究,研究发现,老年2型糖尿病患者中风、亚临床心区不适标志物和全身性动脉粥样硬化与认知减退具有显著相关性。研究结果在线发表于2013年4月11日的美国《糖尿病护理》(Diabetes Care)杂志上。研

Diabetes Care:糖尿病视网膜病和微量白蛋白尿可预测T2DM患者大量白蛋白尿和肾功能减退

为了评价2型糖尿病患者糖尿病视网膜病(DR)和糖尿病肾病(DN)间的相互作用关系,同时阐明DR和微量白蛋白尿对出现大量白蛋白尿和肾功能减退的影响,来自日本北里大学健康护理中心的Moriya博士等人进行了一项研究,作者认为,蛋白尿和DR应被视为2型糖尿病患者肾脏预后的危险因素。研究结果在线发表于2013年4月25日的美国《糖尿病护理》(Diabetes Care)杂志上。该项研究是日本糖尿病并发症研

Diabetes Res Clin Pr:T2DM患者存在骨矿代谢失衡

在2型糖尿病(T2DM)患者中,为了评估糖尿病和糖尿病肾病对骨矿代谢的影响。来自中国兰州大学第二医院的陈慧教授及其团队进行了一项研究(The effects of diabetes mellitus and diabetic nephropathy on bone and mineral metabolism in T2DM patients),该研究发现T2DM患者表现为骨矿代谢失衡,而且,合并